scholarly journals Drug repurposing for Alzheimer’s disease: Selective serotonin reuptake inhibitors

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Praveen P. Nekkar Rao ◽  
Gary Tin ◽  
Tarek Mohamed ◽  
Arash Shakeri ◽  
Amy Trinh Pham
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Drug Repurposing ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin

Selective Serotonin Reuptake Inhibitors and Trazodone for Treatment of Depression, Psychosis, and Behavioral Symptoms in Patients With Dementia

2000 ◽  
Vol 12 (S1) ◽  
pp. 245-251 ◽  
Author(s):  
David L. Sultzer
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Adverse Effects ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Behavioral Symptoms ◽  
Selective Serotonin ◽  
Clinical Aspects ◽  
Treatment Of Depression

Depression, psychosis, agitation, and aggression are fundamental clinical aspects of Alzheimer's disease (AD) and other dementia syndromes. Although behavioral, environmental, and pharmacologic interventions often help ameliorate these symptoms, the efficacy of specific interventions is uncertain, and adverse effects of medications are common.

Effect of Selective Serotonin Reuptake Inhibitors in Alzheimer’s Disease with Comorbid Depression

Drugs & Aging ◽  
2012 ◽  
Vol 29 (10) ◽  
pp. 793-806 ◽  
Author(s):  
Amir A. Sepehry ◽  
Philip E. Lee ◽  
Ging Yuek R. Hsiung ◽  
B. Lynn Beattie ◽  
Claudia Jacova
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Comorbid Depression

Opportunities for Drug Repurposing of Serotonin Reuptake Inhibitors: Potential Uses in Inflammation, Infection, Cancer, Neuroprotection, and Alzheimer’s Disease Prevention

2021 ◽  
Author(s):  
Madeline J. Nykamp ◽  
Charles F. Zorumski ◽  
Angela M. Reiersen ◽  
Ginger E. Nicol ◽  
John Cirrito ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serotonin Reuptake ◽  
Depressive Disorders ◽  
Drug Repurposing ◽  
Serotonin Reuptake Inhibitors ◽  
Neuroprotective Activity ◽  
Current Evidence ◽  
Ongoing Research ◽  
Neoplastic Processes

AbstractSerotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of indications including depressive disorders, anxiety, and chronic pain. Besides inhibiting the serotonin transporter, these medications have broad-spectrum properties in many systems. Their roles have been studied in cancer, Alzheimer’s disease, and infectious processes. The COVID-19 pandemic highlighted the importance of drug repurposing of medications already in use. We conducted a narrative review of current evidence and ongoing research on drug repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and neuroprotective activity. SRIs may have clinical use as repurposed agents for a wide variety of conditions including but not limited to COVID-19, Alzheimer’s disease, and neoplastic processes. Further research, particularly randomized controlled trials, will be necessary to confirm the utility of SRIs for new indications.

Sign in / Sign up

Export Citation Format

Share Document